Literature DB >> 29453932

Neurotrophin-3 restores synaptic plasticity in the striatum of a mouse model of Huntington's disease.

Victor G Gómez-Pineda1, Francisco M Torres-Cruz1, César I Vivar-Cortés1, Elizabeth Hernández-Echeagaray1.   

Abstract

AIMS: Neurotrophin-3 (NT-3) is expressed in the mouse striatum; however, it is not clear the NT-3 role in striatal physiology. The expression levels of mRNAs and immune localization of the NT-3 protein and its receptor TrkC are altered in the striatum following damage induced by an in vivo treatment with 3-nitropropionic acid (3-NP), a mitochondrial toxin used to mimic the histopathological hallmarks of Huntington's disease (HD). The aim of this study was to evaluate the role of NT-3 on corticostriatal synaptic transmission and its plasticity in both the control and damaged striatum.
METHODS: Corticostriatal population spikes were electrophysiologically recorded and striatal synaptic plasticity was induced by high-frequency stimulation. Further, the phosphorylation status of Trk receptors was tested under conditions that imitated electrophysiological experiments.
RESULTS: NT-3 modulates both synaptic transmission and plasticity in the striatum; nonetheless, synaptic plasticity was modified by the 3-NP treatment, where instead of producing striatal long-term depression (LTD), long-term potentiation (LTP) was obtained. Moreover, the administration of NT-3 in the recording bath restored the plasticity observed under control conditions (LTD) in this model of striatal degeneration.
CONCLUSION: NT-3 modulates corticostriatal transmission through TrkB stimulation and restores striatal LTD by signaling through its TrkC receptor.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  Huntington's disease; NT-3; TrkC; neurodegeneration; neurotrophins

Mesh:

Substances:

Year:  2018        PMID: 29453932      PMCID: PMC6489824          DOI: 10.1111/cns.12824

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  42 in total

1.  Physiological and morphological plasticity induced by chronic treatment with NT-3 or NT-4/5 in hippocampal slice cultures.

Authors:  Lucia Schwyzer; José María Mateos; Mathias Abegg; Lotty Rietschin; Lucette Heeb; Scott M Thompson; Andreas Lüthi; Beat H Gähwiler; R Anne McKinney
Journal:  Eur J Neurosci       Date:  2002-11       Impact factor: 3.386

2.  High resolution mapping of the binding site of TrkA for nerve growth factor and TrkC for neurotrophin-3 on the second immunoglobulin-like domain of the Trk receptors.

Authors:  R Urfer; P Tsoulfas; L O'Connell; J A Hongo; W Zhao; L G Presta
Journal:  J Biol Chem       Date:  1998-03-06       Impact factor: 5.157

3.  Inactivation of succinate dehydrogenase by 3-nitropropionate.

Authors:  C J Coles; D E Edmondson; T P Singer
Journal:  J Biol Chem       Date:  1979-06-25       Impact factor: 5.157

Review 4.  Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.

Authors:  L A Raymond; V M André; C Cepeda; C M Gladding; A J Milnerwood; M S Levine
Journal:  Neuroscience       Date:  2011-08-27       Impact factor: 3.590

5.  Mice heterozygous for neurotrophin-3 display enhanced vulnerability to excitotoxicity in the striatum through increased expression of N-methyl-D-aspartate receptors.

Authors:  J Torres-Peraza; S Pezzi; J M Canals; N Gavaldà; J M García-Martínez; E Pérez-Navarro; J Alberch
Journal:  Neuroscience       Date:  2006-11-01       Impact factor: 3.590

6.  The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro.

Authors:  R Ventimiglia; P E Mather; B E Jones; R M Lindsay
Journal:  Eur J Neurosci       Date:  1995-02-01       Impact factor: 3.386

7.  Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.

Authors:  Carlos Cepeda; Raymond S Hurst; Christopher R Calvert; Elizabeth Hernández-Echeagaray; Oanh K Nguyen; Emily Jocoy; Lindsey J Christian; Marjorie A Ariano; Michael S Levine
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

8.  NT-3-mediated TrkC receptor activation promotes proliferation and cell survival of rodent progenitor oligodendrocyte cells in vitro and in vivo.

Authors:  S Kumar; M A Kahn; L Dinh; J de Vellis
Journal:  J Neurosci Res       Date:  1998-12-15       Impact factor: 4.164

9.  Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine.

Authors:  P Calabresi; P Gubellini; B Picconi; D Centonze; A Pisani; P Bonsi; P Greengard; R A Hipskind; E Borrelli; G Bernardi
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

10.  Presynaptic protein synthesis required for NT-3-induced long-term synaptic modulation.

Authors:  H Shawn Je; Yuanyuan Ji; Ying Wang; Feng Yang; Wei Wu; Bai Lu
Journal:  Mol Brain       Date:  2011-01-07       Impact factor: 4.041

View more
  4 in total

1.  Tolfenamic Acid Attenuates 3-Nitropropionic Acid-Induced Biochemical Alteration in Mice.

Authors:  Peng Liu; Yinjie Li; Danyang Liu; Xuefei Ji; Tianyan Chi; Lin Li; Libo Zou
Journal:  Neurochem Res       Date:  2018-08-17       Impact factor: 3.996

Review 2.  Molecular Pathophysiological Mechanisms in Huntington's Disease.

Authors:  Anamaria Jurcau
Journal:  Biomedicines       Date:  2022-06-17

3.  Neurotrophin-3 restores synaptic plasticity in the striatum of a mouse model of Huntington's disease.

Authors:  Victor G Gómez-Pineda; Francisco M Torres-Cruz; César I Vivar-Cortés; Elizabeth Hernández-Echeagaray
Journal:  CNS Neurosci Ther       Date:  2018-02-17       Impact factor: 5.243

4.  Molecular Regulatory Mechanism and Toxicology of Neurodegenerative Processes in MPTP/Probenecid-Induced Progressive Parkinson's Disease Mice Model Revealed by Transcriptome.

Authors:  Weiwei Yang; Wenwen Hao; Zhuo Meng; Shiyan Ding; Xiaodi Li; Tao Zhang; Weixiao Huang; Lian Xu; Yu Zhang; Jian Yang; Xiaosong Gu
Journal:  Mol Neurobiol       Date:  2020-09-30       Impact factor: 5.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.